The approval introduces a selective dopamine D1/D5 receptor partial agonist as a new oral treatment option for adults with Parkinson's disease.

SK Biopharmaceuticals has secured exclusive global rights to 1ST Biotherapeutics' preclinical Parkinson's disease candidate 1ST-104 in a deal worth up to $314.8 million.

Lexeo Therapeutics has agreed to acquire Mantle Therapeutics for up to $21.3 million, adding four Friedreich ataxia development programmes to its pipeline.

The FDA has approved Aqneursa as the first treatment specifically indicated for ataxia in adults and children with ataxia-telangiectasia weighing at least 15kg.

UpFront Diagnostics has secured CE mark approval for LVOne, a rapid blood test designed to identify large-vessel-occlusion stroke in pre-hospital settings.

Average annual compensation for US neurologists reached $371,087 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in neurology.

The FDA has approved Zanvastro as the first treatment for Alexander disease in paediatric and adult patients.

The clearance extends FDA-authorised blood-based assessment of Alzheimer’s-associated amyloid pathology to younger symptomatic adults, providing clinicians with a less invasive alternative to PET imaging and cerebrospinal fluid testing.

The approval provides clinicians with a new PET imaging agent to identify tau neurofibrillary tangle pathology in adults undergoing assessment for Alzheimer's disease, complementing existing diagnostic tools.

The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.

The orexin receptor agonist provides adults with a treatment that targets the underlying loss of orexin signalling rather than managing individual symptoms separately.

The proposed acquisition would add Xycota’s preclinical CNS pipeline and exosome-based delivery platform to NexTel Medical, including lead programme XYCO-01 for frontotemporal dementia.

The orexin receptor agonist provides adults with a treatment that targets the underlying loss of orexin signalling rather than managing individual symptoms separately.

The all-stock transaction combines complementary central nervous system portfolios spanning neuroscience and addiction medicine, creating a larger commercial-stage company with a broader product portfolio and pipeline.

The Medscape Neurologist Compensation Report 2026 shows US neurologist earnings continuing on a familiar trajectory: